IMMU Mendus AB (publ)

0.3376USD3.430 SEK · STO-4.72%Mkt Cap: 21.70M USDP/E: —

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for t…

Key Statistics

Company
Market Cap21.70M USD
Enterprise Value17.24M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.15M USD
Revenue/Share—
Last Price0.3376 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees18
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0022239950
Valuation
P/E (Trailing)—
P/E (Forward)-7.00
PEG—
EV/EBITDA-1.88
EV/Revenue—
P/S—
P/B0.41
EPS (TTM)-0.17 USD
EPS (Forward)-0.05 USD
52W Range
0.33760% of range0.8357
52W High0.8357 USD
52W Low0.3376 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-19.36%
ROA-18.03%
ROIC-20.86%
ROCE-18.71%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.03M USD
CapEx (TTM)30.22K USD
FCF Margin—
FCF Yield4.81%
Net Debt-3.72M USD
Net Debt/EBITDA0.41
Net Debt/FCF-3.56
Balance Sheet
Debt/Equity0.03
Current Ratio0.83
Quick Ratio0.77
Book Value/Sh0.83 USD
Cash/Share0.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 3, 2024
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.292 USD
Upside (mean)+875.2%
Target Range1.663 USD – 4.921 USD
1.663+875.2% to mean4.921
# Analysts2
Ownership
Shares Out.62.08M
Float23.07M
Insiders62.84%
Institutions16.06%
Technical
SMA 500.5596 (-39.7%)
SMA 2000.5539 (-39.1%)
Beta1.01
S&P 52W Chg12.00%
Avg Vol (30d)44.07K
Avg Vol (10d)82.45K
Technical Indicators
RSI (14)24.1
MACD-0.5295
MACD Signal-0.3709
MACD Hist.-0.1586
BB Upper0.6255 USD
BB Middle0.4839 USD
BB Lower0.3423 USD
BB Width58.51%
ATR (14)0.0575 USD
Vol Ratio (20d)0.71x

About Mendus (STO: IMMU)

›

Mendus (STO: IMMU) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 18 employees.

The shares were at 3.430 SEK on 19 November 2026, down 41.9% over 52 weeks. Its 52-week range is 3.430 SEK to 8.490 SEK, and it trades at the bottom of that range.

Its market capitalisation is 220.49M SEK.

Mendus reports return on equity of -19.4% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 37.83M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.